1. Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial 
Holly M Burke, PhD, Mario Chen, PhD, Mercy Buluzi, BSc, Rachael Fuchs, MS, Silver Wevill, MPH, Lalitha Venkatasubramanian, BS, Leila Dal Santo, MPH, Bagrey Ngwira, PhD 
The Lancet Global Health 
Volume 6, Issue 5, Pages e568-e578 (May 2018)
DOI: /S X(18)
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

2. Figure 1 Participant flow diagram
*N=738 participants were screened for eligibility, but all data from four participants were excluded due to issues with informed consent.
The Lancet Global Health 2018 6, e568-e578DOI: ( /S X(18) )
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

3. Figure 2 Cumulative probability of continuation of DMPA
DMPA=depot medroxyprogesterone acetate. Discontinuation events were not measured at 12 months.
The Lancet Global Health 2018 6, e568-e578DOI: ( /S X(18) )
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions